# Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

> **NCT03862170** · PHASE3 · TERMINATED · sponsor: **CR-CSSS Champlain-Charles-Le Moyne** · enrollment: 158 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ciprofloxacin
- **DRUG:** Cefazolin

## Key facts

- **NCT ID:** NCT03862170
- **Lead sponsor:** CR-CSSS Champlain-Charles-Le Moyne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-10
- **Primary completion:** 2020-02
- **Final completion:** 2023-02
- **Target enrollment:** 158 (ACTUAL)
- **Why stopped:** Covid-19 pandemic
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862170, "Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03862170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*